Latest news
25 items- SECReShape Lifesciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Vyome Holdings, Inc (0001427570) (Filer)
- SECSEC Form 424B5 filed by ReShape Lifesciences Inc.424B5 - Vyome Holdings, Inc (0001427570) (Filer)
- SECReShape Lifesciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Vyome Holdings, Inc (0001427570) (Filer)
- PRVyome closes Merger Transaction, Will Trade on Nasdaq as HIND TomorrowVyome Therapeutics, Inc. ("Vyome"), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (NASDAQ:RSLS). The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol "HIND." About Vyome Vyome is building a healthcare platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory cond
- SECSEC Form 10-Q filed by ReShape Lifesciences Inc.10-Q - ReShape Lifesciences Inc. (0001427570) (Filer)
- PRVyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HINDEffective as of Commencement of Trading on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company's previously announced merger with ReShape Lifesciences (NASDAQ:RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol "HIND." "Nasdaq's approval is right on track and now we are marching forward to ring the bell on our planned listing date this
- PRVyome Announces New Board of Directors with Deep MIT and AI TiesHeavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ:RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which include four Massachusetts Institute of Technology (MIT) alums, are all persons with prior
- SECReShape Lifesciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ReShape Lifesciences Inc. (0001427570) (Filer)
- PRReShape Lifesciences Announces Shareholder Approval of Merger with Vyome TherapeuticsExpected to be Effective as of Commencement of Trading on August 15, 2025 ReShape Lifesciences® (NASDAQ:RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." "Vyome's vision is expansive with several promising assets and we are focused on building a healthcare platform spanning the US-India innovation corridor," sai
- SECSEC Form 425 filed by ReShape Lifesciences Inc.425 - ReShape Lifesciences Inc. (0001427570) (Subject)
- SECSEC Form 425 filed by ReShape Lifesciences Inc.425 - ReShape Lifesciences Inc. (0001427570) (Subject)
- SECSEC Form 8-K filed by ReShape Lifesciences Inc.8-K - ReShape Lifesciences Inc. (0001427570) (Filer)
- SECSEC Form 425 filed by ReShape Lifesciences Inc.425 - ReShape Lifesciences Inc. (0001427570) (Subject)
- SECSEC Form 425 filed by ReShape Lifesciences Inc.425 - ReShape Lifesciences Inc. (0001427570) (Subject)
- PRReShape Lifesciences® Announces Partial Adjournment of Special Meeting of StockholdersPartial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR Proposals 2 and 3 by Calling 1-877-750-8310 (from the U.S. and Canada) or +1-412-232-3651 (from other countries) IRVINE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it conducted a Special Meeting of Stockholders and partially adjourned the meeting for Proposal 2, the proposal to approve the sale of substantially all of ReShape's assets to Ninjour Health Int
- PRReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon SummitIRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host its inaugural Lap-Band® Surgeon Summit, taking place August 1-3, 2025 in Nashville, Tennessee. Dr. Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program, and Chief of the Division of Bariatric Surgeons, will direct the Summit, where she and other faculty will present to over 20 leading Lap-Band® surgeons. "Our inaugural Lap-Band® Surgeon Summit brings together leading bariatric surgeons and underscores our contin
- SECSEC Form 425 filed by ReShape Lifesciences Inc.425 - ReShape Lifesciences Inc. (0001427570) (Subject)
- PRReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling 1-877-750-8310 IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a Special Meeting of Stockholders of ReShape Lifesciences Inc. to be held at 11:30 am ET on July 24, 2025. After a thorough strategic review, the ReShape Board of Directors unanimously determined that a merger with Vyome Therapeutics, Inc. (Vyome), a private clinical-stag
- SECSEC Form 425 filed by ReShape Lifesciences Inc.425 - ReShape Lifesciences Inc. (0001427570) (Subject)
- SECSEC Form 425 filed by ReShape Lifesciences Inc.425 - ReShape Lifesciences Inc. (0001427570) (Subject)
- SECReShape Lifesciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ReShape Lifesciences Inc. (0001427570) (Filer)
- SECReShape Lifesciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - ReShape Lifesciences Inc. (0001427570) (Filer)
- PRReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon SystemIRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8, 2025 the U.S. Patent and Trademark Office (USPTO) will issue U.S. Patent 12,350,179, entitled, "Intragastric Device." The patent, related to the Company's application 18/241,151 and notice of allowance received in April, covers claims for an intragastric balloon system, comprising a swallowable capsule with a self-sealing fill valve and a degradable release valve designed to deflate and open the valve around three months after inflation with saline liquid, and configured for natural excretion aft
- PRReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity RequirementIRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's stockholders equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed. On May 28, 2025, Nasdaq notified the Company that its securities were subject to delisting from Nasdaq based on the C
- SECSEC Form 425 filed by ReShape Lifesciences Inc.425 - ReShape Lifesciences Inc. (0001427570) (Subject)
RSLS FAQ
7 questionsWhat does ReShape Lifesciences Inc. do?
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly...Where does RSLS stock trade?
ReShape Lifesciences Inc. (RSLS) is listed on NASDAQ.What sector and industry is RSLS in?
ReShape Lifesciences Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did ReShape Lifesciences Inc. go public?
ReShape Lifesciences Inc. (RSLS) completed its IPO in 2016.What are analysts saying about RSLS?
ReShape Lifesciences Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $800.00 price target on 2021-10-08. Recent price targets cluster around $800.00.What companies are similar to RSLS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare RSLS side-by-side with any of them on Quantisnow.How can I track RSLS on Quantisnow?
Quantisnow aggregates ReShape Lifesciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RSLS to receive live email and push alerts on every new disclosure.